WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2024 Issue has been successfully launched on NOVEMBER 2024.

Abstract

TO STUDY THE EFFICACY & SAFETY OF ALLOPURINOL ALONE & IN COMBINATION WITH FEBUXOSTAT IN HYPERURICEMIC PATIENTS.

Dr. Tafazzul Hussain, Dr. Musarrat Sultana, Dr. Shamaila Khalid, *Prof. Dr. Syed Saud Hasan, Prof. Dr. Fuad Shaikh and Dr. Nabeel Hasan

ABSTRACT

Introduction: Uric acid is an important constituent, enlist in numbers of physiological & pathological activities in the human body which may undergo to different diseases. Hyperuricemia is recognized, when uric acid raised more than 6.8 mg/dL. Xanthine oxidase inhibitors are the key drugs in reducing the sUA. Objective: Interventional clinical study, conducted at Medical OPD, Civil Hospital Karachi, during the period October 2018 to April 2019. To assess the improvement, safety and tolerability of Allopurinol 300mg/daily & combination of Allopurinol plus Febuxostat 80mg/daily in asymptomatic hyperuricemic patients. Material & Methods: The designed study was approved by BASR & ERB of Hamdard University Karachi. Initially 70 enrolled patients, 60-patients of sUA>6.8 mg/dl were registered, after fulfilled the inclusion and exclusion criteria and written consent, detail history and biochemical assessments measured at day 0, repeated at day 30, 60 and 90, keep in case record file, for final analysis. Patients divided Group A, (Allopurinol) & B (Allopurinol plus Febuxostat) treated & sUA, biochemical assessments, to estimate the improvement, safety and tolerability of the drugs. Results: Group-A baseline uric acid mean 8.79 ± 0.98 change to 6.40 ± 0.86 with percentage change was 27%, while in Group-B treated patients sUA mean 9.22±0.83 to 5.96 ± 0.68 with percentage change was 39%. Mean difference ± SD of serum uric acid in Group-A is 2.39±1.15 with Group-B mean is 3.62 ± 0.87. Drug safety was determined by adverse effects and blood examination, follow up at day-90 from baseline. Conclusion: Improvement reported by mean reduction of uric acid & no reported serious adverse effects, results were highly significant.

Keywords: Allopurinol, Febuxostat, Uric acid, Serum creatinine, Blood chemistry.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More